Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET

Company Participants

Keri Mattox – Chief Communications and Administration Officer

Ivan Tornos – President and Chief Executive Officer

Suky Upadhyay – Executive Vice President and Chief Financial Officer

Conference Call Participants

Robbie Marcus – JPMorgan

Drew Ranieri – Morgan Stanley

Matt Taylor – Jefferies

Shagun Singh – RBC Capital Markets

Josh Jennings – TD Cowen

Larry Biegelsen – Wells Fargo

Chris Pasquale – Nephron

Travis Steed – Bank of America

Vijay Kumar – Evercore ISI

Operator

Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet’s Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today November 7. Following today’s presentation, there will be a question-and-answer session. At this time, all participants are in a listen-only mode. [Operator Instructions]

I would now like to turn the conference over to Keri Mattox, Chief Communications and Administration Officer. Please go ahead.

Keri Mattox

Thank you, operator, and good morning, everyone. Welcome to Zimmer Biomet’s third quarter 2023 earnings conference call. Joining me today are Ivan Tornos, our President and CEO; and EVP and CFO, Suky Upadhyay. Before we get started, I’d like to remind you that our comments during this call will include forward-looking statements. Actual results may differ materially from those indicated by the forward-looking statements due to a variety of risks and uncertainties.

Please note, we assume no obligation to update these forward-looking statements even if actual results or future expectations change materially. Please refer to our SEC filings for a detailed discussion of these risks and uncertainties in addition to the inherent limitations of such forward-looking statements.

Additionally, the discussions on this call will include certain non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures is included within our Q3 earnings release, which can be found on our website, zimmerbiomet.com.

With that, I’ll turn the call over to Ivan. Ivan?

Ivan Tornos

Thank you very much, Keri. And good morning, and greetings, everyone from Warsaw, Indiana, the orthopedic capital of the world, welcome to our Q3 earnings call. My first call as the CEO [indiscernible] organization really grateful that all of you are joining us here this morning.

I’d like to begin by sharing how truly excited I am to be in the new role. Team to be a very inspiring time, not just in musculoskeletal health, which it is, but also in med-tech in general. Simply put the space is not what it used to be just so five years ago. When you look at orthopedics, when you look at the entire category, it’s changed, it’s changed a lot. Groundbreaking technologies are shaping how procedures are done beyond the backlog and continuing femoral demographics, global demand for treatment is higher than it has historically been